Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

IASO Bio acquires MediSix to expand CAR-T reach into T-cell malignancies

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Asia-Pacific

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

IASO Bio has acquired Singapore-based MediSix Therapeutics, gaining a proprietary T-cell fratricide-prevention platform and a Phase I CAR-T clinical asset targeting CD7-positive T-cell malignancies, expanding its cell therapy portfolio beyond existing anti-BCMA products.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You gain a novel CAR-T technology that bypasses a key technical hurdle in T-cell malignancies this week. Building or partnering on T-cell focused cell therapies just got more accessible with a proven platform based in Singapore.

◆ Coverage

1 source · 13 Aug 2026

◆ Related on Wire

◆ Topics

Biotechcell-therapycar-tacquisitiont-cell-malignanciesclinical-development